Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells

Hormone Molecular Biology and Clinical Investigation

Volumn 10, Issue 2, 2012, Pages 273-279

  Weber, Axel ^a   Borghouts, Corina ^a   Delis, Natalia ^a   Mack, Laura ^a   Brill, Boris ^a   Bernard, Anne Charlotte ^a,b   Coqueret, Olivier ^a   Groner, Bernd ^a,c  

^a Institute for Biomedical Research   (United Kingdom)

^b Paul Papin Cancer Center   (France)

^c Institute for Biomedical Research   (United Kingdom)

Author keywords

colorectal cancer; drug resistance; peptide aptamer; signal transducer and activator of transcription 3 (Stat3)

Indexed keywords

CETUXIMAB; FIRTECAN; FLUOROURACIL; IRINOTECAN; PEPTIDE APTAMER; STAT3 PROTEIN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CELL CLONE; CELL DEATH; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DIMERIZATION; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MORBIDITY; PRIORITY JOURNAL; RADIOSENSITIVITY; SENESCENCE; WESTERN BLOTTING;

EID: 84996797376     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2012-0014     Document Type: Article

References (25)

1. Chabner BA., Roberts TG., Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun MJ. Cancer statistics., 2008. CA Cancer J Clin 2008;58:71-96.
3. Hsiang YH., Hertzberg R., Hecht S., Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
4. Conti JA., Kemeny NE., Saltz LB., Huang Y., Tong WP., Chou TC., Sun M., Pulliam S., Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
5. Segal NH., Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-19.
6. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 2008;448:63-76.
7. Arafa El-SA, Zhu Q., Barakat BM., Wani G., Zhao Q., El-Mahdy MA., Wani AA. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoino-sitide 3-kinase/Akt signaling pathway. Cancer Res 2009;69: 8910-7.
8. Weisberg E., Sattler M., Ray A., Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010;29:5120-34.
9. Groner B., Lucks P., Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008;19:341-50.
10. Masuda M., Wakasaki T., Suzui M., Toh S., Joe AK., Weinstein IB. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 2010;10:117-26.
11. Barré B., Vigneron A., Perkins N., Roninson IB., Gamelin E., Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11.
12. Duan Z., Foster R., Bell DA., Mahoney J., Wolak K., Vaidya A., Hampel C., Lee H., Seiden MV. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006;12:5055-63.
13. Courapied S., SellierH, deCarné Tréces son S., Vigneron A., Bernard AC., Gamelin E., Barré B., Coqueret O. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem 2010;285:26765-78.
14. Wegrzyn J., Potla R., Chwae YJ., Sepuri NB., Zhang Q., Koeck T., Derecka M., Szczepanek K., Szelag M., Gornicka A., Moh A., Moghaddas S., Chen Q., Bobbili S., Cichy J., Dulak J., Baker DP., Wolfman A., Stuehr D., Hassan MO., Fu XY., Avadhani N., Drake JI., Fawcett P., Lesnefsky EJ., Larner AC. Function of mitochondrial Stat3 in cellular respiration. Science 2009;323: 793-7.
15. Vigneron A., Gamelin E., Coqueret O. The EGFR-STAT3 oncogenic pathway up-regulates the Emel endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res 2008;68:815-25.
16. Borghouts C., Kunz C., Delis N., Groner B. Monomeric recombinant peptide aptamers are required for efficient intracel-lular uptake and target inhibition. Mol Cancer Res 2008;6: 267-81.
17. Nagel-Wolfrum K., Buerger C., Wittig I., Butz K., Hoppe-Seyler F., Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apopto-sis in tumor cells. Mol Cancer Res 2004;2:170-82.
18. Schust J., Sperl B., Hollis A., Mayer TU., Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42.
19. Pitts TM., Morrow M., Kaufman SA., Tentler JJ., Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009;8:342-9.
20. Bose D., Zimmerman LJ., Pierobon M., Petricoin E., Tozzi F., Parikh A., Fan F., Dallas N., Xia L., Gaur P., Samuel S., Liebler DC., Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011;105:1759-67.
21. Dallas NA., Xia L., Fan F., Gray MJ., Gaur P., van Buren G., 2nd, Samuel S., Kim MP., Lim SJ., Ellis LM. Chemoresistant colorectal cancer cells., the cancer stem cell phenotype., and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-7.
22. George JA., Chen T., Taylor CC. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 2005;65:10381-8.
23. Le XF., Bast RC., Jr. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011;12:260-9.
24. Lin L., Fuchs J., Li C., Olson V., Bekaii-Saab T., Lin J. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH/CD133 stem cell-like human colon cancer cells. Biochem Biophys Res Commun 2011;416:246-51.
25. Huang S., Chen M., Shen Y., Shen W., Guo H., Gao Q., Zou X. Inhibition of activated Stat3 reverses drug resistance to chemo-therapeutic agents in gastric cancer cells. Cancer Lett 2012;315: 198-205.